

Resource Summary Report

Generated by [nidm-terms](#) on Sep 4, 2026

EGFR antibody [EP38Y]

RRID:AB_869579

Type: Antibody

Proper Citation

Abcam Cat# ab52894, RRID:AB_869579

Antibody Information

URL: http://antibodyregistry.org/AB_869579

Proper Citation: Abcam Cat# ab52894, RRID:AB_869579

Target Antigen: EGFR antibody [EP38Y]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Immunoprecipitation; Western Blot; Immunohistochemistry - fixed; ICC/IF, IHC-P, IP, WB

Antibody Name: EGFR antibody [EP38Y]

Description: This monoclonal targets EGFR antibody [EP38Y]

Target Organism: Human, Rat, Mouse

Antibody ID: AB_869579

Vendor: Abcam

Catalog Number: ab52894

Record Creation Time: 20231110T075702+0000

Record Last Update: 20260829T134820+0000

Ratings and Alerts

No rating or validation information has been found for EGFR antibody [EP38Y].

No alerts have been found for EGFR antibody [EP38Y].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Ibrahim M, et al. (2026) NF1 Loss Remodels Tumor Niches for Immune Evasion. bioRxiv : the preprint server for biology.

Peng M, et al. (2026) MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells. Cell stem cell, 33(5), 800.

Song H, et al. (2026) Hijacking ERAD for targeted degradation of transmembrane proteins. Cell, 189(6), 1768.

Zhuang X, et al. (2026) Receptor-ubiquitination-targeting antibody-drug conjugates for enhanced endocytosis and lysosomal delivery. Cell chemical biology, 33(4), 506.

Pini A, et al. (2026) β -adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. British journal of pharmacology, 183(10), 2497.

Pang Z, et al. (2026) Mapping cellular targets of covalent cancer drugs in the entire mammalian body. Cell, 189(3), 725.

Tzouanas CN, et al. (2025) Hepatic adaptation to chronic metabolic stress primes tumorigenesis. Cell.

Sorensen JR, et al. (2025) Inhibition of ErbB2 mitigates secondary denervation after traumatic muscle injury. The Journal of physiology, 603(23), 7531.

Wang Y, et al. (2025) Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance. Immunity.

Bojang P, et al. (2025) LINE1 insertion into the NACC2 locus disrupts the HDM2 axis and activates lung oncogenic signaling. NPJ precision oncology, 9(1), 255.

Ibrahim M, et al. (2025) NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma. Cancer research, 85(17), 3348.

Zidel A, et al. (2025) Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. Scientific reports, 15(1), 16964.

Ren L, et al. (2025) Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Cancer cell.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. *Cell reports. Medicine*, 6(2), 101929.

Xia L, et al. (2024) Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells. *Cancer research*, 84(3), 479.

Roy A, et al. (2024) Impact of Interleukin-6 Activation and Arthritis on Epidermal Growth Factor Receptor (EGFR) Activation in Sensory Neurons and the Spinal Cord. *International journal of molecular sciences*, 25(13).

Jin N, et al. (2024) Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study. *BMC medicine*, 22(1), 342.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Chen W, et al. (2024) GGT5 as a promising prognostic biomarker and its effects on tumor cell progression in gastric cancer. *Translational cancer research*, 13(8), 4459.

Dong Y, et al. (2024) TSPAN4 influences glioblastoma progression through regulating EGFR stability. *iScience*, 27(8), 110417.